PRTK - Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01 revenue of $29.6M beats by $0.42M
- Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q2 GAAP EPS of -$0.33 beats by $0.01 .
- Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M .
- Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
For further details see:
Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M